Anthony Bihl

Chairman of the Board

Mr. Bihl has served on the Board since March 2008. Mr. Bihl is an experienced executive with more than 30 years in leadership of global healthcare businesses including a broad base of operational, financial, and senior executive positions. Mr. Bihl is currently the CEO of Bioventus LLC, a global provider of ortho biologic products, effective December 2, 2013. He also serves as a director on the board of Greatbatch Inc.. From 2011 to 2012, Mr. Bihl was Group President of American Medical Systems (“AMS”), a subsidiary of Endo Pharmaceuticals, in Minneapolis, Minnesota. From 2008 to 2011, Mr. Bihl was the President and Chief Executive Officer of AMS. From 2000 to 2007, Mr. Bihl served in various senior leadership positions at Bayer Healthcare Diagnostics Division including Vice President of Finance, Senior Vice President of Business Planning and Administration, and President, Diagnostics Division. Subsequently, he was Chief Executive Officer of Siemens DX upon the acquisition of Bayer’s Diagnostics Division by Siemens AG.

Paul Walker


Dr. Walker joined Spectral as President and CEO in April 2001. Previously, he held the position of COO of the Toronto General Hospital, and was Surgeon in Chief and Vice President of the Surgical Directorate of the University Hospital Network. Dr. Walker was an active Vascular Surgeon and the Director of the Intensive Care Program, and Professor of Medicine and Laboratory Medicine at the University of Toronto.

A pioneer in the area of endotoxin and its role in sepsis, and the co-inventor of the Endotoxin Activity Assay (EAA™), Dr. Walker is a frequent participant at leading sepsis and critical care conferences, has been a keynote speaker at symposiums focusing on the role of endotoxin in sepsis, and is the author of over 100 scientific publications. He received his M.D. from the University of Western Ontario, his Ph.D. from the Salgrenska University of Göteborg, Sweden, and is a graduate of the Advanced Management Program from Harvard School of Business.

Kevin Giese


Mr. Giese has a B.A. in economics, a law degree, and an M.B.A. He has practiced law in Vancouver, was president of Mr. Lube U.S. (acquired by Pennzoil), was a director and CFO of TSX-listed NQL Drilling Tools (acquired by National Oilwell Varco), and has sat in management roles and on the board of directors of a number of private and other TSX listed companies. He is a past advisory board member of the Institute of Corporate Directors (Canada) and is currently a member of the Board of Directors of BioAlberta. Kevin Giese is the founding President, CEO and Director of Medwell Capital Corp. (formerly BioMS Medical Corp.), a biotechnology company dedicated to the development and commercialization of innovative therapies, with an emphasis on the treatment of Multiple Sclerosis. In 2005 he received the BioAlberta Award for Entrepreneurship.

Guillermo Herrera


Mr. Herrera is a seasoned global healthcare executive with more than 30 years of experience. Mr. Herrera is the Chairman and founder of Pinnacle Biologics Inc. Previously, Mr. Herrera spent 24 years at Abbott Laboratories, most recently serving as Senior Vice President, International Operations and President of Abbott International. In this role, Mr. Herrera was accountable for international commercial operations including sales and marketing of pharmaceutical, nutritional and hospital products in markets outside the US. In 2004, Mr. Herrera joined Rosetta Partners LLC as the Partner and Principal in charge of the private equity division. Mr. Herrera received a B.A. in industrial economics from the Universidad del Valle, Colombia, and his M.B.A. from the Kellogg Graduate School of Management at Northwestern University.

Dr. Masayuki Kaneko


Dr. Kaneko is currently acting General Manager of Toray’s pharmaceutical and medical products division and has over twenty years of experience in pharmaceutical research and business development. Dr. Kaneko has managed a number of international joint ventures and co-development initiatives for Toray’s pharmaceutical business. He replaces Mr. Koichiro Takeshita, who served on the Spectral Board since 2013.

William Stevens


Mr. Stevens has served on the Board since September 2014. Mr. Stevens brings over 20 years of experience in the capital markets and investment industry to the Company. He is currently the President of GS Investment Corp, and was Managing Director of Westerkirk Capital Corp., both private investment management companies. He has held senior roles in investment banking and private equity and has a successful track record of value creation for shareholders. Mr. Stevens’ educational background includes an M.B.A from the Harvard University Graduate School of Business Administration.

135 The West Mall , Unit 2 •  Toronto, Ontario  •  M9C 1C2  Canada

Tel: 1.416.626.3233  •  Toll Free: 1.888.426.4264  •  Fax: 1.416.626.7383